WO2004100892A3 - Novel fibroblast growth factors and methods of use thereof - Google Patents

Novel fibroblast growth factors and methods of use thereof Download PDF

Info

Publication number
WO2004100892A3
WO2004100892A3 PCT/US2004/014623 US2004014623W WO2004100892A3 WO 2004100892 A3 WO2004100892 A3 WO 2004100892A3 US 2004014623 W US2004014623 W US 2004014623W WO 2004100892 A3 WO2004100892 A3 WO 2004100892A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fibroblast growth
growth factors
novel fibroblast
fgf
Prior art date
Application number
PCT/US2004/014623
Other languages
French (fr)
Other versions
WO2004100892A2 (en
Inventor
Jeffrey Peterson
Paul Sciore
Peter Mezes
Henri Lichenstein
Michael Jeffers
William Larochelle
Marie Ruiz-Martinez
Galina Chernaya
Original Assignee
Curagen Corp
Jeffrey Peterson
Paul Sciore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Jeffrey Peterson, Paul Sciore filed Critical Curagen Corp
Priority to JP2006532928A priority Critical patent/JP2007516223A/en
Priority to AU2004238332A priority patent/AU2004238332A1/en
Priority to CA002525107A priority patent/CA2525107A1/en
Priority to EP04751821A priority patent/EP1626696A2/en
Publication of WO2004100892A2 publication Critical patent/WO2004100892A2/en
Publication of WO2004100892A3 publication Critical patent/WO2004100892A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to compositions and methods of treatment of various conditions, including but are not limited to, stroke, wound healing, and joint diseases (e.g., osteoarthritis and rheumatoid arthritis). More particularly, the present invention relates to compositions comprising a member of the fibroblast growth factor family, FGF-CX (also known as CG53135-05 or FGF-20), its related polypeptides, nucleic acids encoding such polypeptides, and their uses for treating a condition, such as but is not limited to, stroke, wound healing, and joint diseases (e.g., osteoarthritis and rheumatoid arthritis).
PCT/US2004/014623 2003-05-09 2004-05-10 Novel fibroblast growth factors and methods of use thereof WO2004100892A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006532928A JP2007516223A (en) 2003-05-09 2004-05-10 Novel fibroblast growth factor and method of use thereof
AU2004238332A AU2004238332A1 (en) 2003-05-09 2004-05-10 Novel fibroblast growth factors and methods of use thereof
CA002525107A CA2525107A1 (en) 2003-05-09 2004-05-10 Novel fibroblast growth factors and methods of use thereof
EP04751821A EP1626696A2 (en) 2003-05-09 2004-05-10 Novel fibroblast growth factors and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46935303P 2003-05-09 2003-05-09
US60/469,353 2003-05-09

Publications (2)

Publication Number Publication Date
WO2004100892A2 WO2004100892A2 (en) 2004-11-25
WO2004100892A3 true WO2004100892A3 (en) 2008-04-10

Family

ID=33452279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014623 WO2004100892A2 (en) 2003-05-09 2004-05-10 Novel fibroblast growth factors and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1626696A2 (en)
JP (1) JP2007516223A (en)
AU (1) AU2004238332A1 (en)
CA (1) CA2525107A1 (en)
WO (1) WO2004100892A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056885B1 (en) * 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
CA2428084A1 (en) * 2000-11-06 2002-08-01 Curagen Corporation Treatment of inflammatory bowel disease using growth factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
AU2004238332A1 (en) 2004-11-25
JP2007516223A (en) 2007-06-21
AU2004238332A2 (en) 2004-11-25
EP1626696A2 (en) 2006-02-22
CA2525107A1 (en) 2004-11-25
WO2004100892A2 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
WO2002008284A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002014368A8 (en) Proteins and nucleic acids encoding the same
WO2002006339A3 (en) Proteins and nucleic acids encoding same
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2005019256A3 (en) Muteins of tear lipocalin
WO2003037932A3 (en) Human coagulation factor vii polypeptides
WO1999053040A3 (en) Human nucleic acid sequences from ovarian tumour tissue
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002050277A3 (en) Protein and nucleic acids encoding same
WO2002057453A3 (en) Polypetides and nucleic acids encoding same
WO2002068649A3 (en) Proteins and nucleic acids encoding same
EP2392655A3 (en) Coagulation factor VII polypeptides
WO2001090155A3 (en) Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
WO2002098917A3 (en) Human proteins and nucleic acids encoding same
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
WO2001081578A3 (en) Novel proteins and nucleic acids encoding same
WO2005024006A8 (en) Coagulation factor VII polypeptides
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2002016599A3 (en) Proteins and nucleic acids encoding same
WO2004094651A3 (en) Novel human polypeptides encoded by polynucleotides
WO2004100892A3 (en) Novel fibroblast growth factors and methods of use thereof
WO2001066747A8 (en) Proteins named fctrx and nucleic acids encoding same
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002099116A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2525107

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006532928

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004238332

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004751821

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004238332

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004751821

Country of ref document: EP